^
    Back
    Association details:
    Biomarker:ARSI overexpression
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:XAV-939 (Wnt signalling pathway inhibitor, TNKS inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    J Clin Lab Anal
    Title:

    Arylsulfatase I is a prognostic biomarker for head and neck squamous cell carcinoma and Pan-cancer

    Published date:
    07/23/2022
    Excerpt:
    Arylsulfatase I was highly expressed in 15 cancer types, with significant expressions in HNSC….Elevated ARSI expressions conferred poor tolerance to daporinad and sinularin, but increased cell sensitivity to dasatinib and XAV939.
    DOI:
    10.1002/jcla.24600